| Hypoglycemia
Baqsimi vs Gvoke HypoPen
Side-by-side clinical, coverage, and cost comparison for hypoglycemia.Deep comparison between: Baqsimi vs Gvoke Hypopen with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGvoke Hypopen has a higher rate of injection site reactions vs Baqsimi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gvoke Hypopen but not Baqsimi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Baqsimi
Gvoke Hypopen
At A Glance
Intranasal
As needed
Antihypoglycemic agent
SC injection
Single dose
Glucagon receptor agonist
Indications
- Hypoglycemia
- Hypoglycemia
Dosing
Hypoglycemia 3 mg as one intranasal actuation into one nostril; if no response after 15 minutes, an additional 3 mg dose from a new device may be administered while waiting for emergency assistance.
Hypoglycemia (adults and pediatric patients >=12 years) 1 mg SC injection into lower abdomen, outer thigh, or outer upper arm; may repeat 1 mg from a new device after 15 minutes if no response while awaiting emergency assistance.
Hypoglycemia (pediatric patients 2 to <12 years, <45 kg) 0.5 mg SC injection into lower abdomen, outer thigh, or outer upper arm; may repeat 0.5 mg from a new device after 15 minutes if no response while awaiting emergency assistance.
Hypoglycemia (pediatric patients 2 to <12 years, >=45 kg) 1 mg SC injection into lower abdomen, outer thigh, or outer upper arm; may repeat 1 mg from a new device after 15 minutes if no response while awaiting emergency assistance.
Diagnostic aid (stomach, duodenal bulb, duodenum, small bowel) 0.2 mg to 0.5 mg IV slow push (GVOKE VialDx only), diluted to 0.45 mg/mL with 0.9% Sodium Chloride Injection, administered under medical supervision.
Diagnostic aid (colon) 0.5 mg to 0.75 mg IV slow push (GVOKE VialDx only), diluted to 0.45 mg/mL with 0.9% Sodium Chloride Injection, administered under medical supervision.
Contraindications
- Pheochromocytoma, due to risk of substantial increase in blood pressure
- Insulinoma, due to risk of hypoglycemia
- Prior hypersensitivity reaction to glucagon or any excipient in BAQSIMI
- Pheochromocytoma, due to risk of substantial increase in blood pressure
- Insulinoma, due to risk of hypoglycemia
- Prior hypersensitivity reaction to glucagon or any excipient in GVOKE or GVOKE VialDx
- Glucagonoma (GVOKE VialDx only), due to risk of hypoglycemia
Adverse Reactions
Most common (>=2%) Nausea, headache, vomiting, upper respiratory tract irritation (nasal discomfort, nasal congestion, sneezing, cough, epistaxis)
Serious Substantial increase in blood pressure in pheochromocytoma patients, hypoglycemia in insulinoma patients, serious hypersensitivity reactions including anaphylactic shock, lack of efficacy in patients with decreased hepatic glycogen
Other Dysgeusia, pruritus, tachycardia, hypertension, nasal pruritus, throat irritation, parosmia
Most common (>=2%) Nausea, vomiting, injection site edema, headache (adults); nausea, hypoglycemia, vomiting, headache, hyperglycemia, abdominal pain, injection site discomfort, urticaria (pediatric patients).
Serious Substantial increase in blood pressure in patients with pheochromocytoma, hypoglycemia in patients with insulinoma, serious hypersensitivity reactions including anaphylactic shock, lack of efficacy in patients with decreased hepatic glycogen, necrolytic migratory erythema, hyperglycemia with IV diagnostic use in patients with diabetes mellitus, blood pressure and heart rate increases with IV diagnostic use in patients with cardiac disease, hypoglycemia in patients with glucagonoma with IV diagnostic use.
Postmarketing Necrolytic migratory erythema with continuous glucagon infusion, hypoglycemia and hypoglycemic coma, hypoglycemia in patients taking indomethacin.
Pharmacology
Glucagon activates hepatic glucagon receptors, stimulating glycogen breakdown and release of glucose from the liver; adequate hepatic glycogen stores are required for the antihypoglycemic effect.
Glucagon activates hepatic glucagon receptors, stimulating glycogen breakdown and glucose release from the liver to raise blood glucose concentration; it also relaxes smooth muscle of the stomach, duodenum, small bowel, and colon.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Baqsimi
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (9/12)
Gvoke Hypopen
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Baqsimi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Gvoke Hypopen
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Baqsimi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Gvoke Hypopen
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Baqsimi.
No savings programs available for Gvoke Hypopen.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BaqsimiView full Baqsimi profile
Gvoke HypopenView full Gvoke Hypopen profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.